WWOX基因在良恶性胸腔积液中的异常表达研究
|
摘要
目的：通过检测wwox基因6-8外显子mRNA在良、恶性胸腔积液中的表达,探讨WWOX基因在良、恶性胸腔积液临床鉴别诊断中的价值。
方法：根据病理学诊断结果,将来自2007年9月-2008年6月天津胸科医院胸内科住院患者的76例胸腔积液标本分为两组,其中良性胸腔积液组20例,肺癌合并恶性胸腔积液组56例。胸穿抽取胸腔积液10ml,提取RNA；经逆转录合成cDNA,再经PCR反应,用电泳直接检测cDNA的扩增产物用逆转录-聚合酶链反应(RT-PCR)技术进行良、恶性性胸腔积液WWOX基因mRNA6-8外显子表达的检测。进一步分析恶性胸腔积液患者WWOX6-8外显子表达与临床特征(包括性别、吸烟情况、肿瘤组织类型、分期)的关系。数据用SPSS13.0软件处理,两样本率的比较用四格表资料的确切概率法(Fisher's精确概率法)及χ2检验法,P<0.05为有显著性差异。
结果：
1.恶性胸腔积液组：56例标本中,39例(69.6%)标本未能扩增出WWOX基因6-8外显子片段；而56例标本中,其中31例经胸水细胞学及胸水沉淀物病理确诊肺癌的样本均未能扩增出WWOX基因6-8外显子片段,而胸水细胞学及胸水沉淀物病理阴性,最后经胸膜活检证实肺癌的25例恶性胸水样本中,有8例未能扩增出WWOX基因6-8外显子片段。良性胸腔积液组：20例标本全部(100%)扩增出WWOX基因6-8外显子片段。经统计方法处理,χ2值为6.765(p<0.05),两者相比较差异有统计学意义。胸腔积液WWOX基因6-8外显子转录本缺失诊断恶性胸腔积液的敏感度为69.6%,特异度为100%,阳性预测值为100%,阴性预测值为100%。
2.肺癌并恶性胸腔积液WWOX基因6-8外显子缺失率在性别、是否重度吸烟及肿瘤组织类型(非小细胞肺癌与小细胞肺癌)有显著性差异(分别p=0.001、p=0.001、p=0.041),但与肿瘤临床分期无显著性差异(p=0.27)。男性、长期大量吸烟者及非小细胞肺癌肺癌患者恶性胸腔积液WWOX基因6-8外显子缺失率较高。
结论：研究表明,位于16q23.3-24.1的WWOX基因在恶性胸腔积液中存在较高的6-8外显子转录本缺失率,提示WWOX基因可能在恶性胸腔积液的发生、发展中起一定作用；WWOX基因6-8外显子转录本的丢失是恶性胸腔积液的分子标志之一；WWOX基因6-8外显子检测可作为鉴别良、恶性胸腔积液辅助手段
Objective:To detect the abnormal expression of WWOX (WW domain containing oxidoreductase) exons 6-8 In human lung benign and malignant pleural effusion at mRNA leval and to draw some conclusion concering whether loss of WWOX exons 6-8 play an role in the tumorigenesie of malignant pleural effusion.
Methods:76 pleural effusion samples come from Tianjin Chest Hospital Medical Department in 2007 September to 2008 June in, According to cytology results samples were divided into two groups:20 in benign effusions and 56 in malignant effusions which from lung cancer. Take 10ml of pleural effusion, extracted total RNA, react cDNA by RT, after PCR 5μl of sample electrophoresis, observe and photographed in ultraviolet light. To analysis the relationship of the expression of WWOX exons 6-8 with clinical charactors (gender, smoking, histological type, stage),we use chisquare test and exact probability test of contingency table by spss 13.0 sofeware, P<0.05 have statistics difference.
Results:(1) malignant effusions groups,39 (69.6%) specimens failed PCR amplification of DNA fragments of the expected length,in 56 cases of malignant pleural effusion,39 specimens failed to amplify exon 6-8 WWOX gene fragment, while the samples of 20 (100%) patients with benign pleural effusions WWOX gene was amplified exon 6-8 fragment (χ2 is 6.765,p<0.05).31 cases of pleural effusion by pleural fluid cytology and pathological diagnosis of lung cancer sediment samples cannot amplificate exon 6-8 WWOX gene fragments, and pleural fluid cytology and pleural effusion sediment pathology negative.Finally, in 25 cases of malignant pleural effusion of lung cancer samples confirmed by pleural biopsy,8 cases failed to amplify exon 6-8 WWOX gene fragments.
(2) We further observed the transcript loss of WWOX exons 6-8 was significantly higher in the men compared to the women (p=0.001), it is also higher in the smokers compared to the none-smokers (p=0.001)and squamous cell carcinomas compare to adenocarcinomas(p=0.041), But it was not associated with TNM stage(p=0.27). There is higher transcript loss of WWOX exons 6-8 in male,heavily smoking,non small cell lung cancer patients.
Conclusion:The study shows that, at 16q23.3-24.1 of the WWOX gene in non-small cell lung cancer there is a higher transcript exon 6-8 deletion rate,it suggests that WWOX gene may play an important role in the development of malignant pleural effusion,the loss of WWOX gene transcripts exon 6-8 is an molecular marker of malignant pleural effusion; WWOX gene exon 6-8 mRNA can be used as indicators in identifying benign and malignant pleural effusion.
方法：根据病理学诊断结果,将来自2007年9月-2008年6月天津胸科医院胸内科住院患者的76例胸腔积液标本分为两组,其中良性胸腔积液组20例,肺癌合并恶性胸腔积液组56例。胸穿抽取胸腔积液10ml,提取RNA；经逆转录合成cDNA,再经PCR反应,用电泳直接检测cDNA的扩增产物用逆转录-聚合酶链反应(RT-PCR)技术进行良、恶性性胸腔积液WWOX基因mRNA6-8外显子表达的检测。进一步分析恶性胸腔积液患者WWOX6-8外显子表达与临床特征(包括性别、吸烟情况、肿瘤组织类型、分期)的关系。数据用SPSS13.0软件处理,两样本率的比较用四格表资料的确切概率法(Fisher's精确概率法)及χ2检验法,P<0.05为有显著性差异。
结果：
1.恶性胸腔积液组：56例标本中,39例(69.6%)标本未能扩增出WWOX基因6-8外显子片段；而56例标本中,其中31例经胸水细胞学及胸水沉淀物病理确诊肺癌的样本均未能扩增出WWOX基因6-8外显子片段,而胸水细胞学及胸水沉淀物病理阴性,最后经胸膜活检证实肺癌的25例恶性胸水样本中,有8例未能扩增出WWOX基因6-8外显子片段。良性胸腔积液组：20例标本全部(100%)扩增出WWOX基因6-8外显子片段。经统计方法处理,χ2值为6.765(p<0.05),两者相比较差异有统计学意义。胸腔积液WWOX基因6-8外显子转录本缺失诊断恶性胸腔积液的敏感度为69.6%,特异度为100%,阳性预测值为100%,阴性预测值为100%。
2.肺癌并恶性胸腔积液WWOX基因6-8外显子缺失率在性别、是否重度吸烟及肿瘤组织类型(非小细胞肺癌与小细胞肺癌)有显著性差异(分别p=0.001、p=0.001、p=0.041),但与肿瘤临床分期无显著性差异(p=0.27)。男性、长期大量吸烟者及非小细胞肺癌肺癌患者恶性胸腔积液WWOX基因6-8外显子缺失率较高。
结论：研究表明,位于16q23.3-24.1的WWOX基因在恶性胸腔积液中存在较高的6-8外显子转录本缺失率,提示WWOX基因可能在恶性胸腔积液的发生、发展中起一定作用；WWOX基因6-8外显子转录本的丢失是恶性胸腔积液的分子标志之一；WWOX基因6-8外显子检测可作为鉴别良、恶性胸腔积液辅助手段
Objective:To detect the abnormal expression of WWOX (WW domain containing oxidoreductase) exons 6-8 In human lung benign and malignant pleural effusion at mRNA leval and to draw some conclusion concering whether loss of WWOX exons 6-8 play an role in the tumorigenesie of malignant pleural effusion.
Methods:76 pleural effusion samples come from Tianjin Chest Hospital Medical Department in 2007 September to 2008 June in, According to cytology results samples were divided into two groups:20 in benign effusions and 56 in malignant effusions which from lung cancer. Take 10ml of pleural effusion, extracted total RNA, react cDNA by RT, after PCR 5μl of sample electrophoresis, observe and photographed in ultraviolet light. To analysis the relationship of the expression of WWOX exons 6-8 with clinical charactors (gender, smoking, histological type, stage),we use chisquare test and exact probability test of contingency table by spss 13.0 sofeware, P<0.05 have statistics difference.
Results:(1) malignant effusions groups,39 (69.6%) specimens failed PCR amplification of DNA fragments of the expected length,in 56 cases of malignant pleural effusion,39 specimens failed to amplify exon 6-8 WWOX gene fragment, while the samples of 20 (100%) patients with benign pleural effusions WWOX gene was amplified exon 6-8 fragment (χ2 is 6.765,p<0.05).31 cases of pleural effusion by pleural fluid cytology and pathological diagnosis of lung cancer sediment samples cannot amplificate exon 6-8 WWOX gene fragments, and pleural fluid cytology and pleural effusion sediment pathology negative.Finally, in 25 cases of malignant pleural effusion of lung cancer samples confirmed by pleural biopsy,8 cases failed to amplify exon 6-8 WWOX gene fragments.
(2) We further observed the transcript loss of WWOX exons 6-8 was significantly higher in the men compared to the women (p=0.001), it is also higher in the smokers compared to the none-smokers (p=0.001)and squamous cell carcinomas compare to adenocarcinomas(p=0.041), But it was not associated with TNM stage(p=0.27). There is higher transcript loss of WWOX exons 6-8 in male,heavily smoking,non small cell lung cancer patients.
Conclusion:The study shows that, at 16q23.3-24.1 of the WWOX gene in non-small cell lung cancer there is a higher transcript exon 6-8 deletion rate,it suggests that WWOX gene may play an important role in the development of malignant pleural effusion,the loss of WWOX gene transcripts exon 6-8 is an molecular marker of malignant pleural effusion; WWOX gene exon 6-8 mRNA can be used as indicators in identifying benign and malignant pleural effusion.
引文
[1]Preuβat K, Beetz C, Schrey M,et al. Expression of Voltage-gated Potassium Channels Kv1.3 and Kv1,5 in Human Gliomas[J].Neuroscience Letters,2003,346:33-36.
[2]Bednarek A K, Laflin KJ,Daniel RL,et al. WWOX,a novel WW Domain containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer.Cancer Res,2000,60 (8):2140-2145.
[3]YendamuriS, KurokiT, TrapassoF, et al. WW domain containing oxidoreductase gene expression is altered in non-small cell lung cancer[J]. Cancer Res,2003,63 (4): 878-881.
[4]Dhillon VS, Hmsain SK, Ray GN, et al. Expression of aphidicolin-induced fragile sites and their relationship between genetic susceptibility in breast cancer,ovarian Cancer,and non-small cell lung cancer patients. Teratog Carcinog Mutagen,2003,26 (Suppl 1):35-45.
[5]Bednarek AK, Laflin KJ,Daniel RL,et al. WWOX,a novel WW Domain containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer.Cancer Res,2000,60 (8):2140-2145.
[6]Carter S,Ewing CM,Ward WS. Allelic loss of chromosomes 16q and 10q in human prostate cancer. Proc Natl Acad Sci USA,1990,87 (22):8751-8755.
[7]Nishida N,Fukuda Y,Kokuryu H,et al. Accumulation of allelic loss on arms of chromosomes 13q,16q and 17q in t he advanced stages of human hepatocellular carcinoma. Int J Cancer,1992,51(6):862-868.
[8]Wang L,Darling J,Zhang J S,et al. Allele-specific late replication and fragility of the most active common fragile site, FRA3B.Hum Mol Genet,1999,8 (3):431-437.
[9]Mangelsdorf M,Ried K,Woollat t E,et al. Chromosomal fragile site FRA16D and DNA instability in cancer. Cancer Res,2000,60 (60):1683-1689.
[10]Chesi M, Bergsagel PL. Frequent dysregulation of the C-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. Blood,1998,91 (12):4457-4463.
[11]Chen T, Sahin A, A ldaz C, et al. Deletion map of chromosome 16q in ductal carcinoma in situ of the breast:refining a putative tumor suppressor gene region. Cancer Res,1996,56 (24):5605-5609.
[12]Toledo BG, Sola JJ, Lozano MD, et al. Loss of FHIT protein expression is related to high proliferation, low apoptosis and worse prognosis in non-small-cell lung cancer. Mod Pathol,2004,17 (4):440-448.
[13]ChangNS, PrattN, Heath J, et al. Hyaluronidase induction of a WWDomain-containing oxido-reductase that enhances tumor necrosis factor cytotoxicity[J]. J Biol Chem,2001,276 (5):3361-3370.
[14]Tuner BC, OtteyM, Zimonjic DB, et al. The fragile histidine triad/common chromosome fragile site 3B locus and repair-deficient cancer[J]. Cancer Res,2002, 62 (14):4054-4060.
[15]Nunez MI, Ludes2Meyers J, Abba MC, et al. Frequent loss of WWOX expression in breast cancer:correlation with estrogen receptor status[J]. Breast Cancer Res Treat,2005,89 (2):99-105.
[16]Huebner K,Croce CM. FRA3B and ot her common fragile sites:t he weakest links. Nat Rev Cancer,2001,1 (3):2142221.
[17]Toledo BG, Sola JJ,Lozano MD, et al. Loss of FHIT protein expression is related to high proliferation, low apoptosis and worse prognosis in non2small2cell lung cancer. Mod Pat hol,2004,17 (4):4402448.
[18]Aqeilan RI, Kuroki T, Pekarsky Y, et al. Loss of WWOX Expression in gast ric carcinoma. Clin Cancer Res,2004,10 (10):3053-3058.
[19]Gourley C, Paige AJ, Taylor KJ, et al. WWOX mRNA exp-ression p rofile in ep ithelial ovarian cancer supports the role of WWOX variant 1 as a tumor supp ressor, although the role of variant 4 remains unclear [J]. Int J Oncol,2005,26(6): 1681-1689.
[20]Aqeilan RI, Palamarchuk A, Weigel RJ, et al. Physical and functional interactions between t he wwox tumor suppressor protein and t he AP22γt ranscription factor. Cancer Res,2004,64(22):8256-8261.
[21]Ludes-Meyers J H, Bednarek AK, Popescu NC, et al. WWOX, the common chromosomal fragile site, FRA16D,Cancer Gene.Cytogenetic Genome Res,2003,100 (124):101-110.
[22]Aqeilan RI, Kuroki T, Pekarsky Y, et al. Loss of WWOX Expression in gast ric carcinoma. Clin Cancer Res,2004,10 (10):3053-3058.
[23]Yendamuri S, Kuroki T, Trapasso F, et al. WW domain containing oxidoreductase gene exp ression is altered in non-small celllung cancer[J]. Cancer Res,2003,63: 878-881.
[24]Kuroki T, Yendamuri S, Trapasso F, et al. The tumor supp ressor gene WWOX at FRA16D is involved in pancreatic carcinogenesis [J]. Clin Cancer Res,2004,10: 2459-2465.
[25]Nunez MI,Ludes-Meyers J H,Abba MC,et al. Frequent loss ofWWOX expression in breast cancer:correlation wit h est rogenreceptor status. Breast Cancer Res Treat,2005,89(2):99-105.
[26]Ramos D, Abba M, Lopez-Guerrero JA, Rubio J, Solsona E, Almenar S,et al.low Levers of WWOX protein immunoexpression correlate with tumor grde and a less favorable outcome in patients with urinary bladder tumous[J].Histopathology,2008 52(7):831-9.
[27]Pluciennik E, Kusinska R, Potemski P, Kubiak R, Kordek R, Bednarek AK. WWOX--the FRA16D cancer gene:expression correlation with breast cancer progression and prognosis[J]. Eur J Surg Oncol,2006;32(2):153-157.
[28]Aqeilan R I, Trapasso F, Hussain S, et al. Targeted deletion of WWOX reveals a tumor suppressor function. PNAS,2007,104 (10):3949-3954.
[29]Bednarek A, Catherine L, Laflin K, et al. WWOX, the FRA 16D gene, behaves as a suppressor of tumor growth. Cancer Res,2001,61:8068-8073.
[30]Maria INunez, John Ludes-Meyers C, Marcelo Aldaz. WWOX protein expression in normal human tissues [J]. J Mol Hist,2006,37:115-125.
[31]Watanabe A, H ippo Y, Taniguch i H, et al. An opposing view on WWOX protein function as a tumor suppresso r. Cancer Res,2003,63 (24):8629-8633.
[32]NunezMI, Ludes-Meyers J, AbbaMC, et al. Frequent loss of WWOX expression in breast cancer:Correlation with estrogen recep tor status[J]. Breast Cancer Res Treat,2005,89:99-105.
[33]NunezM I, Rosen DG, Ludes-Meyers JH, et al. WWOX proteinexpression varies among ovarian carcinoma histotypes and correlates with less favorable outcome[J]. BMC Cancer,2005,5:64.
[34]FabbriM, IliopoulosD, Trapasso F, et al. WWOX gene restoration prevents lung cancer growth in vitro and in vivo[J]. PNAS,2005,25:15611-15616.
[35]Yendamuri S, Kuroki T, Trapasso F, et al. WW domain containing oxidoreductase gene exp ression is altered in non-small cell lung cancer[J]. Cancer Res,2003,63:878-881.
[36]IliopoulosD, Guler G, Han S Y, et al. WWOX gene restorationp revents lung cancer growth in vitro and in vivo [J]. Oncogene,2005,24:1625-1633.
[37]DonatiV, Fontanini G, Dell'OmodarmeM, et al. WWOX expression in different histological types and subtypes of non-small cell lung cancer[J]. Clin Cancer Res, 2007,13:884-891.
[38]周玉龙,徐永健,张珍祥.WWOX蛋白在非小细胞肺癌中的表达及意义.[J]中华肿瘤杂志,2007,29(4)：297.
[39]周玉龙,徐永健.抑癌基因WWOX在肺腺癌细胞株A549中表达的研究.中国癌症杂志,2005,15(3)：234-237.
[40]Krummel KA, Denison SR, Calhoun E, et al. The common fragile site FRA16D and its associated gene WWOX are highly conserved in the mouse at Fra8 E1 [J]. Genes Chromosomes Cancer,2002,34:154-167.
[41]Aqeilan R I, Trapasso F, Hussain S, et al. Targeted deletion of WWOX reveals a tumor suppressor function [J]. PNAS,2007,104:3949-3954.
[42]Bednarek AK, Keck2Waggoner CL, Daniel RL, et al. WWOX, the FRA16D gene, behaves as a suppressor of tumor growth [J]. Cancer Res,2001,61(22):8068-8073.
[43]Nunez MI, Rosen DG, Ludes-Meyers JH, et al. WWOX protein expression varies among ovarian carcinoma histotypes and correlates with less favorable outcome [J]. BMC Cancer,2005,10 (5):837-843.
[44]Thavathiru E, Ludes2Meyers JH, MacLeod MC, et al. Expression of common chromosomal fragile site genes, WWOX/FRA16D and FH IT/FRA3B is downregulated by exposure to environmental carcinogens, UV, and BPDE but not by IR [J]. Mol Carcinog,2005,44 (3):174-182.
[45]Chang N S, Pratt N, Health J, et al. Hyaluronidase induction of a WW domain-containing oxidoreductase that enhances tumor necrosis factor cytotoxicity. J Biol Chem,2001,276 (5):3361-3370
[46]Chang NS, Doherty J, Ensign A, et al. WOX1 is essential for tumor necrosis factor-, UV light-, staurosporine-, and p53-mediated cell death, and its tyrosine 33-phosphorylated form binds and stabilizes serine 46-phosphorylated p53 [J]. J Biol Chem,2005,280 (52):43100-43108.
[47]Yakicier MC,Legoix P,Vaury C,et al. Identification of homozygous deletions at chromosome 16q23 in aflatoxin B1 exposed hepatocellular carcinoma[J]. Oncogene,2001,20(37):5232-5238.
[48]Gaudio E, Palamarchuk A, Palumbo T, et al. Physical association with WWOX supp resses c2Jun transcrip tional activity [J].Cancer Res,2006,66 (24):11585-11589.
[49]Christina M, Kraemer P, Juliette TJ, et al. A denovo redesign of the WW domain. Protein Sci,2003,12 (5):2194-2205.
[50]Chang NS, Doherty J, Ensign A. JNK1 physically interacts with WW domain-containing oxidoreductase (WOX1) and inhibitsWOX1-mediated apop tosis [J]. J Biol Chem,2003,278 (11):9195-9202.
[51]Kuroki T, Trapasso F, Shiraishi T, et al. Genetic alterations of the tumor suppressor gene WWOX in esophageal squamous cellcarcinoma[J]. Cancer Res, 2002,62:2258-2260.
[52]Aqeilan R I, Pekarsky Y, Herrero JJ, et al. Functional association between WWOX tumor suppressor protein and p73, a p53 homolog[J]. PNAS,2004,101 (13):4401-4406.
[53]Sogame N, Kim M, Abrams JM. Drosophila p53 preserves genomic stability by regulating cell death[J]. Proc Natl Acad Sci,2003,100:4696-4701.
[54]Lee JH, Lee E, Park J, et al. In vivo p53 function is indispensable for DNA damage induced apop totic signaling in Drosophila [J]. FEBS Lett,2003,550:5-10.
[55]Aqeilan R I, Hagan JP, Aqeilan HA, et al. Inactivation of theWWOX Gene accelerates forestomach tumor p rogression in vivo [J]. Cancer Res,2007,67 (12): 5606-5610.
[56]Aqeilan R I, Croce CM. WWOX in biological control and tumorigenesis[J]. J Cell Physiol,2007,212 (2):307-310.
[57]Melino G, De Laurenzi V, Vousden KH. p73:Friend or foe in tumorigenesis[J]. Nat Rev Cancer,2002,2:605-615.
[58]Kaghad M, Bonnet H, Yang A, et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuro blastoma and other human cancers [J]. Cell,1997,90:809-819.
[59]Jost CA,MarinMC, KaelinWJ. p73 is a human p53-related protein that can induce apoptosis[J]. Nature,1997,389:191.
[60]Yang A, WalkerN, Bronson R, et al. p73-deficientmice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours[J]. Nature, 2000,404:99-103.
[61]Inoue T, Stuart J, Leno R, et al. Nuclear import and export signals in control of the p53-related protein p73 [J]. J Biol Chem,2002,277:15053-15060.
[62]Rami I. Aqeilan physical and functional interactions between the WWOX tumor suppressor protein and the AP-2{γ} transcription factor. Cancer Research,2004,64 (15):8256-8261.
[63]Guler G, Iliopoulos D, Guler N, et al. WWOX and Ap2gamma expression levels p redict tamoxifen response [J]. Clin Cancer Res,2007,13 (20):6115-6121
[64]Ishii H, Mimori K, Inageta T, et al. Components of DNA damage checkpoint pathway regulate UV exposure-dependent alterations of gene expression of FH IT and WWOX at chromosome fragile sites[J]. Mol Cancer Res,2005,3 (3):130-138.
[65]Junttila TT, SundvallM, LundinM, et al. Cleavable ErbB4 iso-form in estrogen recep tor-regulated growth of breast cancer cells [J]. Cancer Res,2005,65:1384-1393.
[66]Maatta JA, SundvallM, Junttila TT, et al. Proteolytic cleavage and phosphorylation of a tumor-associated ErbB4 isoform promote ligand-independent survival and cancer cell growth [J].Mol Biol Cell,2006,17:67-79.
[67]Komuro A, NagaiM, Navin NE, et al. WW domain-containing protein YAP associates with ErbB-4 and acts as a co-transcriptional activator for the carboxyl-terminal fragment of ErbB-4 that translocates to the nucleus [J]. J Biol Chem,2003, 278:33334-33341.
[68]Aqeilan R I, DonatiV, Palamarchuk A, et al. WW domain-containing p roteins, WWOX and YAP, compete for interaction with ErbB-4 and modulate its transcriptional function [J]. Cancer Res,2005,65:6764-6772.
[69]Rami I Aqeilan, Valentina Donati. Association of WWOX with ErbB4 in breast cancer [J]. Cancer Res,2007,67:9330-9336.
[70]Schmitz KJ, Grabellus F, Callies R, et al. Relationship and prognostic significance of phospho-(serine166)-murine double minute 2 and Akt activation in node-negative breast cancer with regard to p53 expression[J]. VirchowsArch,2006,448: 16-23.
[71]Chang NS, Hsu LJ, Lin YS, et al. WW domain-containing oxidoreductase:a candidate tumor suppressor [J]. Trends Mol Med,2007,13 (1):12-22.
[72]Aqeilan R I, DonatiV, Palamarchuk A, et al. WW domain-containing proteins, WWOX and YAP, compete for interaction with ErbB-4 and modulate its transcriptional function [J]. Cancer Res,2005,65:6764-6772.
[73]Driouch K, Prydz H, Monese R, et al. Alternative transcrip ts of the candidate tumor supp ressor gene, WWOX, are exp ressed at high levels in human breast tumors [J]. Oncogene,2002,21(12):1832-1840.
[74]IliopoulosD, Guler G, Han SY, et al. Fragile genes as biomarkers:Epigenetic control of WWOX and FH IT in lung, breast and bladder cancer[J]. Oncogene,2005, 24:1625-1633
[75]Aqeilan R I, Trapasso F, Hussain S, et al. Targeted deletion of WWOX reveals a tumor suppressor function [J]. PNAS,2007,104:3949-3954.
[76]Nakayama S, Semba S, Maeda N, Aqeilan RI, Huebner K, Yokozaki H.Role of the WWOX gene,encompassing fragile region FRA16D, in suppression of pancreatic carcinoma cells [J]. Cancer Sci,2008:1370-6.
[77]Cantor JP, Iliopoulos D, Rao AS, Druck T, Semba S, Han SY, et al. Epigenetic modulation of endogenous tumor suppressor expression in lung cancer xenografts suppresses tumorigenicity[J]. Int J Cancer,2007,120(1):24-31.
[78]Aqeilan RI, Kuroki T, Pekarsky Y, Albagha O, Trapasso F, Baffa R,,et al.Loss of WWOX expression in gastric carcinoma[J].Clin Can Res,2004,10(5):3053-3058.
[79]Ramos D, Abba M, Lopez-Guerrero JA, Rubio J, Solsona E, Almenar S,et al.low Levers of WWOX protein immunoexpression correlate with tumor grde and a less favorable outcome in patients with urinary bladder tumous[J].Histopathology,2008 52(7):831-9.
[1]Hahn WC, Weinberg RA. Rules formaking human tumor cells [J]. N Engl J Med, 2002,347:1593-1603.
[2]Bednarek A K,Laflin KJ,Daniel RL,et al. WWOX,a novel WWdomain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer. Cancer Res,2000,60 (8):2140-2145.
[3]Aqeilan RI, Kuroki T, Pekarsky Y, et al. Loss of WWOX Expression in gast ric carcinoma.Clin Cancer Res,2004,10 (10):3053-3058.
[4]Yendamuri S, Kuroki T, Trapasso F, et al. WW domain contai2 ning oxidoreductase gene exp ression is altered in non-small celllung cancer[J]. Cancer Res,2003,63:878-881.
[5]Kuroki T, Yendamuri S, Trapasso F, et al. The tumor supp ressor gene WWOX at FRA16D is involved in pancreatic carcinogenesis [J]. Clin Cancer Res,2004,10: 2459-2465.
[6]Nunez MI,Ludes2Meyers J H,Abba MC,et al. Frequent loss ofWWOX expression in breast cancer:correlation wit h est rogenreceptor status. Breast Cancer Res Treat,2005,89(2):99-105.
[7]Nunez MI,Rosen DG,Ludes2Meyers J H,et al. WWOX proteinexpression varies among ovarian carcinoma histotypes andcorrelates wit h less favorable outcome. BMC Cancer,2005,5 (1):64.
[8]Ramos D, Abba M, Lopez-Guerrero JA, Rubio J, Solsona E, Almenar S,et al.low Levers of WWOX protein immunoexpression correlate with tumor grde and a less favorable outcome in patients with urinary bladder tumous[J].Histopathology,2008 52(7):831-9.
[9]Pluciennik E, Kusinska R, Potemski P, Kubiak R, Kordek R, Bednarek AK. WWOX--the FRA16D cancer gene:expression correlation with breast cancer progression and prognosis[J]. Eur J Surg Oncol,2006;32(2):153-157.
[10]Chen T,Sahin A,Aldaz C, et al. Deletion map of chromosomel6q in ductal carcinoma in situ of the breast:refining a putativetumor suppressor gene region. Cancer Res,1996,56 (24):5605-5609.
[11]Paige AJ, Taylor KJ, Stewart A, et all A 7002kb physical mapofa region of 16q2312 homozygously deleted in multiple cancersand spanning the common f ragile site FRA16D1 Cancer Res,2000,60 (10):1690-1697.
[12]Bednarek AK,Keck-Waggoner CL,Daniel RL,et al. WWOX,the FRA16D gene,behaves as a suppressor of tumor growth [J]. CancerRes,2001,61:8068-8073.
[13]Ilsley JL, SudolM, Winder SJ. The WW domain:linking cellsignalling to the membrane cytoskeleton [J]. Cell Signalling,2002,14:183-189.
[14]MaciasMJ, Wiesner S, SudolM. WW and SH3 domains, twodifferent scaffolds to recognize p roline-rich ligands [J]. FEBS Lett,2002,513:30-37.
[15]Filling C,Bemdt KD,Benach J,et al. Critical residuces for structure and catalysis in short-chain dehydrogenases/reductases [J]. J Biol Chem,2002,277(28):25677-25684.
[16]Chang NS, Schultz L, Hsu LJ, et al.17beta-Estradiol up regulatesand activatesWOX1/WWOXv1 and WOX2/WWOXv2 in vitro:Potential role in cancerous progression of breast and prostate to a premetastatic state in vivo[J]. Oncogene,2005,24:714-723.
[17]Aqeilan R I, Trapasso F, Hussain S, et al. Targeted deletion of WWOX reveals a tumor supp ressor function [J]. PNAS,2007,104:3949-3954.
[18]Chang NS, Doherty J, Ensign A, et al. WOX1 is essential fortumor necrosis factor, UV light, staurosporine, and p53-mediated cell death, and its tyrosine 33-phosphorylated form bindsand stabilizes serine 46-phosphorylated p53 [J]. J Biol Chem,2005,280 (52):43100-43108.
[19]Thavathiru E, Ludes-Meyers JH, MacLeod MC, et al. Expression of common chromosomal fragile site genes, WWOX/FRA16Dand FH IT/FRA3B is down regulated by exposure to environmental carcinogens, UV, and BPDE but not by IR [J]. Mol Carcinog,2005,44 (3):174-182.
[20]Chang NS,Doherty J,Ensign A. JNK1 physically interacts with WWdomaincontaining oxidoreductase (WOX1) and inhibits WOX1-mediated apoptosis[J]. Biol Chem 2003,278:9195-9202.
[21]Chang NS, Hsu LJ, Lin YS, et al. WW domain-containing oxidoreduc tase:A candidate tumor supp ressor [J]. Trends Mol Med,2007,13:12-22.
[22]Aqeilan R I, Pekarsky Y, Herrero JJ, et al. Functional association between WWOX tumor supp ressor protein and p73, a p53 homolog[J]. PNAS,2004,101 (13):4401-4406.
[23]Melino G,De Laurenzi V,Vousden K H. p73:Friend or foe in tumorigenesis[J]. Nat. Rev. Cancer,2002(2):605-615.
[24]Aqeilan R I, Palamarchuk A, Weigel RJ, et al. Physical andfunctional Interactions between the WWOX tumor supp ressor protein and the AP-2y transcription factor [J]. Cancer Res,2004,64:8256-8261.
[25]Guler G, Iliopoulos D, Guler N, et al. WWOX and Ap2gamma expression levels predict tamoxifen response [J]. Clin Cancer Res,2007,13 (20):6115-6121.
[26]Aqeilan RI,Donati V,Palamarchuk A,etal. WW domain-containingproteins,WWOX and YAP,compete for interaction with ErbB-4 andmodulate its transcriptional function[J]. Cancer Res,2005(65):6764-6772.
[27]Gaudio E, Palamarchuk A, Palumbo T, et al. Physical association with WWOX suppresses c-Jun transcriptional activity [J]. Cancer Res,2006,66 (24) 11585-11589.
[28]Ishii H, Mimori K, Inageta T, et al. Components of DNA damage checkpoint pathway regulate UV exposure-dependent alterations of gene expression of FHIT and WWOX at chromosome fragile sites [J]. Mol Cancer Res,2005,3 (3):130-138.
[29]Stein CK, Glover TW, Palmer JL, et al. Direct correlation between FRA3B expression and cigarette smoking. GenesChromosomes Cancer,2002,34 (3):333-340.
[30]Dhillon VS, Hmsain SK, Ray GN, et al. Expression of aphidicolin-induced f ragile sites and t heir relationship between genetic susceptibility in breast cancer,ovarian Cancer,and non-small cell lung cancer patient s. Teratog Carcinog Mutagen,2003,26 (Suppl 1):35-45.
[31]Mangelsdorf M,Ried K,Woollat t E,et al. Chromosomal fragile site FRA16D and DNA instability in cancer. Cancer Res,2000,60 (60):1683-1689.
[32]Kuroki T, Trapasso F, Shiraishi T,et al. Genetic alterations of the tumor suppressor gene WWOX in esophageal squamous cell carcinoma. Cancer Res,2002,62(8):2258-2260.
[33]Paige AJW, Taylor KJ, Taylor C, et al.WWOX:a candidate tumor suppressor gene involved in multiple tumor types. Genetics,2001,98 (20):11417-11422.
[33]Aqeilan R, Kuroki T, Pekarsky Y, et al. Loss of X expression in gastric carcinoma [J]. Clin Cancer Res,2004,10:3053-3058.
[34]NunezM I, Rosen DG, Ludes-Meyers JH, et al. WWOX protein expression varies among ovarian carcinoma histotypes and correlates with less favorable outcome[J]. BMC Cancer,2005,5:64.
[35]Ludes-Meyers JH, Bednarek AK, Popescu NC, et al. WWOX, the common chromosomal fragile site, FRA16D, cancer gene[J].Park SW, Ludes-Meyers J, Zimonjic DB, et al. Frequent down regulation and loss of WWOX gene expression in human hepatocellular carcinoma[J]. Br J Cancer,2004,91:753-759.
[36]Pimenta FJ, Gomes DA, Perdigao PF, et al. Characterization of the tumor supp-ressor gene WWOX in primary human oral squamous cell carcinomas [J]. Int J Cancer, 2006,118:1154-1158.
[37]DonatiV, Fontanini G, Dell'OmodarmeM, et al. WWOX expression in different histological types and subtypes of non-small cell lung cancer[J]. Clin Cancer Res,2007,13:884-891.
[38]NunezMI, Ludes-Meyers J, AbbaMC, et al. Frequent loss of WWOX exp-ression in breast cancer:Correlation with estrogen receptor status[J]. Breast Cancer Res Treat,2005,89:99-105.
[39]Buerger H, Otterbach F, Simon R. Different genetic pathways in the evolution of invasive breast cancer are associated with distinctmorphological subtypes [J]. J Pathol,1999,189:521-526.
[40]秦晓冰,张敬川.乳腺癌中WWOX基因的杂合性缺失及其蛋白表达的研究[J].实用肿瘤学杂志,2007,21(3)：226-229.
[41]Bednarek AK, Keck2Waggoner CL, Daniel RL, et al. WWOX, the FRA16D gene, behaves as a suppressor of tumor growth [J]. Cancer Res,2001,61(22):8068-8073.
[42]Driouch K, Prydz H, Monese R, et al. Alternative transcripts of the candidate tumor suppressor gene, WWOX, are expressed at high levels in human breast tumors [J]. Oncogene,2002,21(12):1832-1840.
[43]王晓,晁岚,藏益秀,等.乳腺癌组织WWOX基因表达及其与ER绝经状态的相关性[J].山东大学学报(医学版),2007,45(9)：920-926.
[44]Pluciennik E, Kusinska R, Potemski P, et al. WWOX-the FRA16D cancer gene: expression correlation with breast cancer progression and p rognosis[J]. Eur J Surg Oncol,2006,32(2):153-157.
[45]Guler G, Uner A, Guler N, et al. The fragile genes FHIT and WWOX are inactivated coordinately in invasive breast carcinoma [J]. Cancer,2004,100: 1605-1614.
[46]Guler G, UnerA, GulerN, et al. Concordant loss of fragile gene exp-ression early in breast cancer development [J]. Pathol Int,2005,55:471-478.
[47]Qin HR, Iliopoulos D, Semba S, et al. A role for the WWOX gene in prostate cancer[J]. Cancer Res,2006,66 (13):6477-6481.
[48]Chang NS, Schultz L, Hsu LJ, et al.17beta-Estradiol up regulatesand activatesWOX1/WWOXv1 and WOX2/WWOXv2 in vitro:Potential role in cancerous p rogression of breast and prostate to ap remetastatic state in vivo[J]. Oncogene,2005,24:714-723.
[49]Mahajan NP, Whang YE, Mohler JL, et al. Activated tyrosine kinase Ackl promotes prostate tumorigenesis:role of Ackl in polyubiquitination of tumor suppressor WWOX[J]. Cancer Res,2005,65 (22):10514-10523.
[50]Gourley C, Paige AJ, Taylor KJ, et al. WWOX mRNA exp ression p rofile in ep ithelial ovarian cancer supports the role of WWOX variant 1 as a tumor supp ressor, although the role of variant 4 remains unclear [J]. Int J Oncol,2005,26(6): 1681-1689.
[51]Paige AJ, Taylor KJ, StewartA, et al. A 700 kb physicalmap of a region of 16q23. 2 homozygously deleted in multip le cancersand spanning the common fragile site FRA16D[J]. Cancer Res,2000,60 (6):1690-1697.
[52]Nunez MI, Rosen DG, Ludes-Meyers JH, et al. WWOX protein expression varies among ovarian carcinoma histotypes and correlates with less favorable outcome [J]. BMC Cancer,2005,10 (5):837-843.
[53]闫洪超,陆晓媛,韩秋峪,等.WWOX mRNA在卵巢上皮性癌组织中的表达及临床意义[J].徐州医学院学报,2007,27(2)：126-128.
[54]IliopoulosD, Guler G, Han SY, et al. Fragile genes as biomarkers:ep igenetic control ofWWOX and FH IT in lung, breast and bladdercancer[J]. Oncogene,2005, 24(9):1625-1633.
[55]周玉龙,徐永健,张珍祥.抑癌基因WWOX在肺腺癌细胞株A549中表达的研究[J].中国癌症杂志,2005,15(3)：234-237.
[56]YendamuriS, KurokiT, TrapassoF, et al. WW domain containingoxidoreductase gene exp ression is altered in non-small cell lung cancer[J]. Cancer Res,2003,63 (4):878-881.
[57]DonatiV, Fontanini G, Dell'OmodarmeM, et al. WWOX expression in different histological types and subtypes of non-small cell lung cancer[J]. Clin Cancer Res, 2007,13:884-891.
[58]Kuroki T,Trapasso F,Shiraishi T,et al. Genetic alterations of tumor suppressor gene WWOX in esophageal squamous cell carcinoma[J]. Cancer Res,2002,62(8):2258-2260.
[59]Yakicier MC,Legoix P,Vaury C,et al. Identification of homozygousdeletions at chromosome 16q23 in aflatoxin B1 exposed hepatocellular carcinoma[J]. Oncogene,2001,20(37):5232-5238.
[60]Park SW,Ludes-Meyers J,Zimonjic DB,et al. Frequent downregulation and loss of WWOX gene exppression in human hepatocellular carcinoma[J]. Br J Cancer,2004,91(4):753-759.
[61]陈锦萍,王效明.PCR检测原发性肝细胞癌WWOX基因表达及意义[J].临床检验杂志,2007,25(5)：364-366.
[62]Matsuo K,Kuroki T,Kitaoka F,et al. Loss of heterozygosity of chromosome 16q in gallbladder carcinoma [J].J Surg Res,2002,102(2):133-136.
[63]顾军,王梅.抑癌基因WWOX在肝外胆管癌中的表达[J].世界华人消化杂志,2007,15(11)：1302-1305.
[64]Kuroki T,Yendamuri S,Trapasso F,et al. The tumor suppressor gene WWOX at FRA16D is involved in pancreatic carcinogenesis [J]. Clin Cancer Res,2004,10(7):2459-2465.
[65]许红霞,周建农.抑癌基因WWOX和FHIT在结直肠癌中的表达及其临床意义[J].南京医科大学学报,2007,27(8)：812-815.
[66]Ishii H, Vecchione A, Furukawa Y, et al. Exp ression of FRA16D/WWOX and FRA3B/FH IT genes in hematopoieticmalignancies[J]. Mol Cancer Res,2003,1 (13):940-947.
[67]Huebner D, Bednarek A, Cat herine L, et all WWOX, the FRA16D gene behaves as a suppressor of tumor growt h1 Cancer Res,2001,61 (15):8068-80731.
[68]Qin HR,Iliopoulos D1A role for the WWOX gene in prostate cancer.Cancer Res,2006,66 (2):123-127.
[69]Akira W, Yoshitaka H, Hirokazu T, et all An opposing view on WWOX protein function as a tumor suppressorl Cancer Research,2003,63 (15) 8629-8633.
[2]Bednarek A K, Laflin KJ,Daniel RL,et al. WWOX,a novel WW Domain containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer.Cancer Res,2000,60 (8):2140-2145.
[3]YendamuriS, KurokiT, TrapassoF, et al. WW domain containing oxidoreductase gene expression is altered in non-small cell lung cancer[J]. Cancer Res,2003,63 (4): 878-881.
[4]Dhillon VS, Hmsain SK, Ray GN, et al. Expression of aphidicolin-induced fragile sites and their relationship between genetic susceptibility in breast cancer,ovarian Cancer,and non-small cell lung cancer patients. Teratog Carcinog Mutagen,2003,26 (Suppl 1):35-45.
[5]Bednarek AK, Laflin KJ,Daniel RL,et al. WWOX,a novel WW Domain containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer.Cancer Res,2000,60 (8):2140-2145.
[6]Carter S,Ewing CM,Ward WS. Allelic loss of chromosomes 16q and 10q in human prostate cancer. Proc Natl Acad Sci USA,1990,87 (22):8751-8755.
[7]Nishida N,Fukuda Y,Kokuryu H,et al. Accumulation of allelic loss on arms of chromosomes 13q,16q and 17q in t he advanced stages of human hepatocellular carcinoma. Int J Cancer,1992,51(6):862-868.
[8]Wang L,Darling J,Zhang J S,et al. Allele-specific late replication and fragility of the most active common fragile site, FRA3B.Hum Mol Genet,1999,8 (3):431-437.
[9]Mangelsdorf M,Ried K,Woollat t E,et al. Chromosomal fragile site FRA16D and DNA instability in cancer. Cancer Res,2000,60 (60):1683-1689.
[10]Chesi M, Bergsagel PL. Frequent dysregulation of the C-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. Blood,1998,91 (12):4457-4463.
[11]Chen T, Sahin A, A ldaz C, et al. Deletion map of chromosome 16q in ductal carcinoma in situ of the breast:refining a putative tumor suppressor gene region. Cancer Res,1996,56 (24):5605-5609.
[12]Toledo BG, Sola JJ, Lozano MD, et al. Loss of FHIT protein expression is related to high proliferation, low apoptosis and worse prognosis in non-small-cell lung cancer. Mod Pathol,2004,17 (4):440-448.
[13]ChangNS, PrattN, Heath J, et al. Hyaluronidase induction of a WWDomain-containing oxido-reductase that enhances tumor necrosis factor cytotoxicity[J]. J Biol Chem,2001,276 (5):3361-3370.
[14]Tuner BC, OtteyM, Zimonjic DB, et al. The fragile histidine triad/common chromosome fragile site 3B locus and repair-deficient cancer[J]. Cancer Res,2002, 62 (14):4054-4060.
[15]Nunez MI, Ludes2Meyers J, Abba MC, et al. Frequent loss of WWOX expression in breast cancer:correlation with estrogen receptor status[J]. Breast Cancer Res Treat,2005,89 (2):99-105.
[16]Huebner K,Croce CM. FRA3B and ot her common fragile sites:t he weakest links. Nat Rev Cancer,2001,1 (3):2142221.
[17]Toledo BG, Sola JJ,Lozano MD, et al. Loss of FHIT protein expression is related to high proliferation, low apoptosis and worse prognosis in non2small2cell lung cancer. Mod Pat hol,2004,17 (4):4402448.
[18]Aqeilan RI, Kuroki T, Pekarsky Y, et al. Loss of WWOX Expression in gast ric carcinoma. Clin Cancer Res,2004,10 (10):3053-3058.
[19]Gourley C, Paige AJ, Taylor KJ, et al. WWOX mRNA exp-ression p rofile in ep ithelial ovarian cancer supports the role of WWOX variant 1 as a tumor supp ressor, although the role of variant 4 remains unclear [J]. Int J Oncol,2005,26(6): 1681-1689.
[20]Aqeilan RI, Palamarchuk A, Weigel RJ, et al. Physical and functional interactions between t he wwox tumor suppressor protein and t he AP22γt ranscription factor. Cancer Res,2004,64(22):8256-8261.
[21]Ludes-Meyers J H, Bednarek AK, Popescu NC, et al. WWOX, the common chromosomal fragile site, FRA16D,Cancer Gene.Cytogenetic Genome Res,2003,100 (124):101-110.
[22]Aqeilan RI, Kuroki T, Pekarsky Y, et al. Loss of WWOX Expression in gast ric carcinoma. Clin Cancer Res,2004,10 (10):3053-3058.
[23]Yendamuri S, Kuroki T, Trapasso F, et al. WW domain containing oxidoreductase gene exp ression is altered in non-small celllung cancer[J]. Cancer Res,2003,63: 878-881.
[24]Kuroki T, Yendamuri S, Trapasso F, et al. The tumor supp ressor gene WWOX at FRA16D is involved in pancreatic carcinogenesis [J]. Clin Cancer Res,2004,10: 2459-2465.
[25]Nunez MI,Ludes-Meyers J H,Abba MC,et al. Frequent loss ofWWOX expression in breast cancer:correlation wit h est rogenreceptor status. Breast Cancer Res Treat,2005,89(2):99-105.
[26]Ramos D, Abba M, Lopez-Guerrero JA, Rubio J, Solsona E, Almenar S,et al.low Levers of WWOX protein immunoexpression correlate with tumor grde and a less favorable outcome in patients with urinary bladder tumous[J].Histopathology,2008 52(7):831-9.
[27]Pluciennik E, Kusinska R, Potemski P, Kubiak R, Kordek R, Bednarek AK. WWOX--the FRA16D cancer gene:expression correlation with breast cancer progression and prognosis[J]. Eur J Surg Oncol,2006;32(2):153-157.
[28]Aqeilan R I, Trapasso F, Hussain S, et al. Targeted deletion of WWOX reveals a tumor suppressor function. PNAS,2007,104 (10):3949-3954.
[29]Bednarek A, Catherine L, Laflin K, et al. WWOX, the FRA 16D gene, behaves as a suppressor of tumor growth. Cancer Res,2001,61:8068-8073.
[30]Maria INunez, John Ludes-Meyers C, Marcelo Aldaz. WWOX protein expression in normal human tissues [J]. J Mol Hist,2006,37:115-125.
[31]Watanabe A, H ippo Y, Taniguch i H, et al. An opposing view on WWOX protein function as a tumor suppresso r. Cancer Res,2003,63 (24):8629-8633.
[32]NunezMI, Ludes-Meyers J, AbbaMC, et al. Frequent loss of WWOX expression in breast cancer:Correlation with estrogen recep tor status[J]. Breast Cancer Res Treat,2005,89:99-105.
[33]NunezM I, Rosen DG, Ludes-Meyers JH, et al. WWOX proteinexpression varies among ovarian carcinoma histotypes and correlates with less favorable outcome[J]. BMC Cancer,2005,5:64.
[34]FabbriM, IliopoulosD, Trapasso F, et al. WWOX gene restoration prevents lung cancer growth in vitro and in vivo[J]. PNAS,2005,25:15611-15616.
[35]Yendamuri S, Kuroki T, Trapasso F, et al. WW domain containing oxidoreductase gene exp ression is altered in non-small cell lung cancer[J]. Cancer Res,2003,63:878-881.
[36]IliopoulosD, Guler G, Han S Y, et al. WWOX gene restorationp revents lung cancer growth in vitro and in vivo [J]. Oncogene,2005,24:1625-1633.
[37]DonatiV, Fontanini G, Dell'OmodarmeM, et al. WWOX expression in different histological types and subtypes of non-small cell lung cancer[J]. Clin Cancer Res, 2007,13:884-891.
[38]周玉龙,徐永健,张珍祥.WWOX蛋白在非小细胞肺癌中的表达及意义.[J]中华肿瘤杂志,2007,29(4)：297.
[39]周玉龙,徐永健.抑癌基因WWOX在肺腺癌细胞株A549中表达的研究.中国癌症杂志,2005,15(3)：234-237.
[40]Krummel KA, Denison SR, Calhoun E, et al. The common fragile site FRA16D and its associated gene WWOX are highly conserved in the mouse at Fra8 E1 [J]. Genes Chromosomes Cancer,2002,34:154-167.
[41]Aqeilan R I, Trapasso F, Hussain S, et al. Targeted deletion of WWOX reveals a tumor suppressor function [J]. PNAS,2007,104:3949-3954.
[42]Bednarek AK, Keck2Waggoner CL, Daniel RL, et al. WWOX, the FRA16D gene, behaves as a suppressor of tumor growth [J]. Cancer Res,2001,61(22):8068-8073.
[43]Nunez MI, Rosen DG, Ludes-Meyers JH, et al. WWOX protein expression varies among ovarian carcinoma histotypes and correlates with less favorable outcome [J]. BMC Cancer,2005,10 (5):837-843.
[44]Thavathiru E, Ludes2Meyers JH, MacLeod MC, et al. Expression of common chromosomal fragile site genes, WWOX/FRA16D and FH IT/FRA3B is downregulated by exposure to environmental carcinogens, UV, and BPDE but not by IR [J]. Mol Carcinog,2005,44 (3):174-182.
[45]Chang N S, Pratt N, Health J, et al. Hyaluronidase induction of a WW domain-containing oxidoreductase that enhances tumor necrosis factor cytotoxicity. J Biol Chem,2001,276 (5):3361-3370
[46]Chang NS, Doherty J, Ensign A, et al. WOX1 is essential for tumor necrosis factor-, UV light-, staurosporine-, and p53-mediated cell death, and its tyrosine 33-phosphorylated form binds and stabilizes serine 46-phosphorylated p53 [J]. J Biol Chem,2005,280 (52):43100-43108.
[47]Yakicier MC,Legoix P,Vaury C,et al. Identification of homozygous deletions at chromosome 16q23 in aflatoxin B1 exposed hepatocellular carcinoma[J]. Oncogene,2001,20(37):5232-5238.
[48]Gaudio E, Palamarchuk A, Palumbo T, et al. Physical association with WWOX supp resses c2Jun transcrip tional activity [J].Cancer Res,2006,66 (24):11585-11589.
[49]Christina M, Kraemer P, Juliette TJ, et al. A denovo redesign of the WW domain. Protein Sci,2003,12 (5):2194-2205.
[50]Chang NS, Doherty J, Ensign A. JNK1 physically interacts with WW domain-containing oxidoreductase (WOX1) and inhibitsWOX1-mediated apop tosis [J]. J Biol Chem,2003,278 (11):9195-9202.
[51]Kuroki T, Trapasso F, Shiraishi T, et al. Genetic alterations of the tumor suppressor gene WWOX in esophageal squamous cellcarcinoma[J]. Cancer Res, 2002,62:2258-2260.
[52]Aqeilan R I, Pekarsky Y, Herrero JJ, et al. Functional association between WWOX tumor suppressor protein and p73, a p53 homolog[J]. PNAS,2004,101 (13):4401-4406.
[53]Sogame N, Kim M, Abrams JM. Drosophila p53 preserves genomic stability by regulating cell death[J]. Proc Natl Acad Sci,2003,100:4696-4701.
[54]Lee JH, Lee E, Park J, et al. In vivo p53 function is indispensable for DNA damage induced apop totic signaling in Drosophila [J]. FEBS Lett,2003,550:5-10.
[55]Aqeilan R I, Hagan JP, Aqeilan HA, et al. Inactivation of theWWOX Gene accelerates forestomach tumor p rogression in vivo [J]. Cancer Res,2007,67 (12): 5606-5610.
[56]Aqeilan R I, Croce CM. WWOX in biological control and tumorigenesis[J]. J Cell Physiol,2007,212 (2):307-310.
[57]Melino G, De Laurenzi V, Vousden KH. p73:Friend or foe in tumorigenesis[J]. Nat Rev Cancer,2002,2:605-615.
[58]Kaghad M, Bonnet H, Yang A, et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuro blastoma and other human cancers [J]. Cell,1997,90:809-819.
[59]Jost CA,MarinMC, KaelinWJ. p73 is a human p53-related protein that can induce apoptosis[J]. Nature,1997,389:191.
[60]Yang A, WalkerN, Bronson R, et al. p73-deficientmice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours[J]. Nature, 2000,404:99-103.
[61]Inoue T, Stuart J, Leno R, et al. Nuclear import and export signals in control of the p53-related protein p73 [J]. J Biol Chem,2002,277:15053-15060.
[62]Rami I. Aqeilan physical and functional interactions between the WWOX tumor suppressor protein and the AP-2{γ} transcription factor. Cancer Research,2004,64 (15):8256-8261.
[63]Guler G, Iliopoulos D, Guler N, et al. WWOX and Ap2gamma expression levels p redict tamoxifen response [J]. Clin Cancer Res,2007,13 (20):6115-6121
[64]Ishii H, Mimori K, Inageta T, et al. Components of DNA damage checkpoint pathway regulate UV exposure-dependent alterations of gene expression of FH IT and WWOX at chromosome fragile sites[J]. Mol Cancer Res,2005,3 (3):130-138.
[65]Junttila TT, SundvallM, LundinM, et al. Cleavable ErbB4 iso-form in estrogen recep tor-regulated growth of breast cancer cells [J]. Cancer Res,2005,65:1384-1393.
[66]Maatta JA, SundvallM, Junttila TT, et al. Proteolytic cleavage and phosphorylation of a tumor-associated ErbB4 isoform promote ligand-independent survival and cancer cell growth [J].Mol Biol Cell,2006,17:67-79.
[67]Komuro A, NagaiM, Navin NE, et al. WW domain-containing protein YAP associates with ErbB-4 and acts as a co-transcriptional activator for the carboxyl-terminal fragment of ErbB-4 that translocates to the nucleus [J]. J Biol Chem,2003, 278:33334-33341.
[68]Aqeilan R I, DonatiV, Palamarchuk A, et al. WW domain-containing p roteins, WWOX and YAP, compete for interaction with ErbB-4 and modulate its transcriptional function [J]. Cancer Res,2005,65:6764-6772.
[69]Rami I Aqeilan, Valentina Donati. Association of WWOX with ErbB4 in breast cancer [J]. Cancer Res,2007,67:9330-9336.
[70]Schmitz KJ, Grabellus F, Callies R, et al. Relationship and prognostic significance of phospho-(serine166)-murine double minute 2 and Akt activation in node-negative breast cancer with regard to p53 expression[J]. VirchowsArch,2006,448: 16-23.
[71]Chang NS, Hsu LJ, Lin YS, et al. WW domain-containing oxidoreductase:a candidate tumor suppressor [J]. Trends Mol Med,2007,13 (1):12-22.
[72]Aqeilan R I, DonatiV, Palamarchuk A, et al. WW domain-containing proteins, WWOX and YAP, compete for interaction with ErbB-4 and modulate its transcriptional function [J]. Cancer Res,2005,65:6764-6772.
[73]Driouch K, Prydz H, Monese R, et al. Alternative transcrip ts of the candidate tumor supp ressor gene, WWOX, are exp ressed at high levels in human breast tumors [J]. Oncogene,2002,21(12):1832-1840.
[74]IliopoulosD, Guler G, Han SY, et al. Fragile genes as biomarkers:Epigenetic control of WWOX and FH IT in lung, breast and bladder cancer[J]. Oncogene,2005, 24:1625-1633
[75]Aqeilan R I, Trapasso F, Hussain S, et al. Targeted deletion of WWOX reveals a tumor suppressor function [J]. PNAS,2007,104:3949-3954.
[76]Nakayama S, Semba S, Maeda N, Aqeilan RI, Huebner K, Yokozaki H.Role of the WWOX gene,encompassing fragile region FRA16D, in suppression of pancreatic carcinoma cells [J]. Cancer Sci,2008:1370-6.
[77]Cantor JP, Iliopoulos D, Rao AS, Druck T, Semba S, Han SY, et al. Epigenetic modulation of endogenous tumor suppressor expression in lung cancer xenografts suppresses tumorigenicity[J]. Int J Cancer,2007,120(1):24-31.
[78]Aqeilan RI, Kuroki T, Pekarsky Y, Albagha O, Trapasso F, Baffa R,,et al.Loss of WWOX expression in gastric carcinoma[J].Clin Can Res,2004,10(5):3053-3058.
[79]Ramos D, Abba M, Lopez-Guerrero JA, Rubio J, Solsona E, Almenar S,et al.low Levers of WWOX protein immunoexpression correlate with tumor grde and a less favorable outcome in patients with urinary bladder tumous[J].Histopathology,2008 52(7):831-9.
[1]Hahn WC, Weinberg RA. Rules formaking human tumor cells [J]. N Engl J Med, 2002,347:1593-1603.
[2]Bednarek A K,Laflin KJ,Daniel RL,et al. WWOX,a novel WWdomain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer. Cancer Res,2000,60 (8):2140-2145.
[3]Aqeilan RI, Kuroki T, Pekarsky Y, et al. Loss of WWOX Expression in gast ric carcinoma.Clin Cancer Res,2004,10 (10):3053-3058.
[4]Yendamuri S, Kuroki T, Trapasso F, et al. WW domain contai2 ning oxidoreductase gene exp ression is altered in non-small celllung cancer[J]. Cancer Res,2003,63:878-881.
[5]Kuroki T, Yendamuri S, Trapasso F, et al. The tumor supp ressor gene WWOX at FRA16D is involved in pancreatic carcinogenesis [J]. Clin Cancer Res,2004,10: 2459-2465.
[6]Nunez MI,Ludes2Meyers J H,Abba MC,et al. Frequent loss ofWWOX expression in breast cancer:correlation wit h est rogenreceptor status. Breast Cancer Res Treat,2005,89(2):99-105.
[7]Nunez MI,Rosen DG,Ludes2Meyers J H,et al. WWOX proteinexpression varies among ovarian carcinoma histotypes andcorrelates wit h less favorable outcome. BMC Cancer,2005,5 (1):64.
[8]Ramos D, Abba M, Lopez-Guerrero JA, Rubio J, Solsona E, Almenar S,et al.low Levers of WWOX protein immunoexpression correlate with tumor grde and a less favorable outcome in patients with urinary bladder tumous[J].Histopathology,2008 52(7):831-9.
[9]Pluciennik E, Kusinska R, Potemski P, Kubiak R, Kordek R, Bednarek AK. WWOX--the FRA16D cancer gene:expression correlation with breast cancer progression and prognosis[J]. Eur J Surg Oncol,2006;32(2):153-157.
[10]Chen T,Sahin A,Aldaz C, et al. Deletion map of chromosomel6q in ductal carcinoma in situ of the breast:refining a putativetumor suppressor gene region. Cancer Res,1996,56 (24):5605-5609.
[11]Paige AJ, Taylor KJ, Stewart A, et all A 7002kb physical mapofa region of 16q2312 homozygously deleted in multiple cancersand spanning the common f ragile site FRA16D1 Cancer Res,2000,60 (10):1690-1697.
[12]Bednarek AK,Keck-Waggoner CL,Daniel RL,et al. WWOX,the FRA16D gene,behaves as a suppressor of tumor growth [J]. CancerRes,2001,61:8068-8073.
[13]Ilsley JL, SudolM, Winder SJ. The WW domain:linking cellsignalling to the membrane cytoskeleton [J]. Cell Signalling,2002,14:183-189.
[14]MaciasMJ, Wiesner S, SudolM. WW and SH3 domains, twodifferent scaffolds to recognize p roline-rich ligands [J]. FEBS Lett,2002,513:30-37.
[15]Filling C,Bemdt KD,Benach J,et al. Critical residuces for structure and catalysis in short-chain dehydrogenases/reductases [J]. J Biol Chem,2002,277(28):25677-25684.
[16]Chang NS, Schultz L, Hsu LJ, et al.17beta-Estradiol up regulatesand activatesWOX1/WWOXv1 and WOX2/WWOXv2 in vitro:Potential role in cancerous progression of breast and prostate to a premetastatic state in vivo[J]. Oncogene,2005,24:714-723.
[17]Aqeilan R I, Trapasso F, Hussain S, et al. Targeted deletion of WWOX reveals a tumor supp ressor function [J]. PNAS,2007,104:3949-3954.
[18]Chang NS, Doherty J, Ensign A, et al. WOX1 is essential fortumor necrosis factor, UV light, staurosporine, and p53-mediated cell death, and its tyrosine 33-phosphorylated form bindsand stabilizes serine 46-phosphorylated p53 [J]. J Biol Chem,2005,280 (52):43100-43108.
[19]Thavathiru E, Ludes-Meyers JH, MacLeod MC, et al. Expression of common chromosomal fragile site genes, WWOX/FRA16Dand FH IT/FRA3B is down regulated by exposure to environmental carcinogens, UV, and BPDE but not by IR [J]. Mol Carcinog,2005,44 (3):174-182.
[20]Chang NS,Doherty J,Ensign A. JNK1 physically interacts with WWdomaincontaining oxidoreductase (WOX1) and inhibits WOX1-mediated apoptosis[J]. Biol Chem 2003,278:9195-9202.
[21]Chang NS, Hsu LJ, Lin YS, et al. WW domain-containing oxidoreduc tase:A candidate tumor supp ressor [J]. Trends Mol Med,2007,13:12-22.
[22]Aqeilan R I, Pekarsky Y, Herrero JJ, et al. Functional association between WWOX tumor supp ressor protein and p73, a p53 homolog[J]. PNAS,2004,101 (13):4401-4406.
[23]Melino G,De Laurenzi V,Vousden K H. p73:Friend or foe in tumorigenesis[J]. Nat. Rev. Cancer,2002(2):605-615.
[24]Aqeilan R I, Palamarchuk A, Weigel RJ, et al. Physical andfunctional Interactions between the WWOX tumor supp ressor protein and the AP-2y transcription factor [J]. Cancer Res,2004,64:8256-8261.
[25]Guler G, Iliopoulos D, Guler N, et al. WWOX and Ap2gamma expression levels predict tamoxifen response [J]. Clin Cancer Res,2007,13 (20):6115-6121.
[26]Aqeilan RI,Donati V,Palamarchuk A,etal. WW domain-containingproteins,WWOX and YAP,compete for interaction with ErbB-4 andmodulate its transcriptional function[J]. Cancer Res,2005(65):6764-6772.
[27]Gaudio E, Palamarchuk A, Palumbo T, et al. Physical association with WWOX suppresses c-Jun transcriptional activity [J]. Cancer Res,2006,66 (24) 11585-11589.
[28]Ishii H, Mimori K, Inageta T, et al. Components of DNA damage checkpoint pathway regulate UV exposure-dependent alterations of gene expression of FHIT and WWOX at chromosome fragile sites [J]. Mol Cancer Res,2005,3 (3):130-138.
[29]Stein CK, Glover TW, Palmer JL, et al. Direct correlation between FRA3B expression and cigarette smoking. GenesChromosomes Cancer,2002,34 (3):333-340.
[30]Dhillon VS, Hmsain SK, Ray GN, et al. Expression of aphidicolin-induced f ragile sites and t heir relationship between genetic susceptibility in breast cancer,ovarian Cancer,and non-small cell lung cancer patient s. Teratog Carcinog Mutagen,2003,26 (Suppl 1):35-45.
[31]Mangelsdorf M,Ried K,Woollat t E,et al. Chromosomal fragile site FRA16D and DNA instability in cancer. Cancer Res,2000,60 (60):1683-1689.
[32]Kuroki T, Trapasso F, Shiraishi T,et al. Genetic alterations of the tumor suppressor gene WWOX in esophageal squamous cell carcinoma. Cancer Res,2002,62(8):2258-2260.
[33]Paige AJW, Taylor KJ, Taylor C, et al.WWOX:a candidate tumor suppressor gene involved in multiple tumor types. Genetics,2001,98 (20):11417-11422.
[33]Aqeilan R, Kuroki T, Pekarsky Y, et al. Loss of X expression in gastric carcinoma [J]. Clin Cancer Res,2004,10:3053-3058.
[34]NunezM I, Rosen DG, Ludes-Meyers JH, et al. WWOX protein expression varies among ovarian carcinoma histotypes and correlates with less favorable outcome[J]. BMC Cancer,2005,5:64.
[35]Ludes-Meyers JH, Bednarek AK, Popescu NC, et al. WWOX, the common chromosomal fragile site, FRA16D, cancer gene[J].Park SW, Ludes-Meyers J, Zimonjic DB, et al. Frequent down regulation and loss of WWOX gene expression in human hepatocellular carcinoma[J]. Br J Cancer,2004,91:753-759.
[36]Pimenta FJ, Gomes DA, Perdigao PF, et al. Characterization of the tumor supp-ressor gene WWOX in primary human oral squamous cell carcinomas [J]. Int J Cancer, 2006,118:1154-1158.
[37]DonatiV, Fontanini G, Dell'OmodarmeM, et al. WWOX expression in different histological types and subtypes of non-small cell lung cancer[J]. Clin Cancer Res,2007,13:884-891.
[38]NunezMI, Ludes-Meyers J, AbbaMC, et al. Frequent loss of WWOX exp-ression in breast cancer:Correlation with estrogen receptor status[J]. Breast Cancer Res Treat,2005,89:99-105.
[39]Buerger H, Otterbach F, Simon R. Different genetic pathways in the evolution of invasive breast cancer are associated with distinctmorphological subtypes [J]. J Pathol,1999,189:521-526.
[40]秦晓冰,张敬川.乳腺癌中WWOX基因的杂合性缺失及其蛋白表达的研究[J].实用肿瘤学杂志,2007,21(3)：226-229.
[41]Bednarek AK, Keck2Waggoner CL, Daniel RL, et al. WWOX, the FRA16D gene, behaves as a suppressor of tumor growth [J]. Cancer Res,2001,61(22):8068-8073.
[42]Driouch K, Prydz H, Monese R, et al. Alternative transcripts of the candidate tumor suppressor gene, WWOX, are expressed at high levels in human breast tumors [J]. Oncogene,2002,21(12):1832-1840.
[43]王晓,晁岚,藏益秀,等.乳腺癌组织WWOX基因表达及其与ER绝经状态的相关性[J].山东大学学报(医学版),2007,45(9)：920-926.
[44]Pluciennik E, Kusinska R, Potemski P, et al. WWOX-the FRA16D cancer gene: expression correlation with breast cancer progression and p rognosis[J]. Eur J Surg Oncol,2006,32(2):153-157.
[45]Guler G, Uner A, Guler N, et al. The fragile genes FHIT and WWOX are inactivated coordinately in invasive breast carcinoma [J]. Cancer,2004,100: 1605-1614.
[46]Guler G, UnerA, GulerN, et al. Concordant loss of fragile gene exp-ression early in breast cancer development [J]. Pathol Int,2005,55:471-478.
[47]Qin HR, Iliopoulos D, Semba S, et al. A role for the WWOX gene in prostate cancer[J]. Cancer Res,2006,66 (13):6477-6481.
[48]Chang NS, Schultz L, Hsu LJ, et al.17beta-Estradiol up regulatesand activatesWOX1/WWOXv1 and WOX2/WWOXv2 in vitro:Potential role in cancerous p rogression of breast and prostate to ap remetastatic state in vivo[J]. Oncogene,2005,24:714-723.
[49]Mahajan NP, Whang YE, Mohler JL, et al. Activated tyrosine kinase Ackl promotes prostate tumorigenesis:role of Ackl in polyubiquitination of tumor suppressor WWOX[J]. Cancer Res,2005,65 (22):10514-10523.
[50]Gourley C, Paige AJ, Taylor KJ, et al. WWOX mRNA exp ression p rofile in ep ithelial ovarian cancer supports the role of WWOX variant 1 as a tumor supp ressor, although the role of variant 4 remains unclear [J]. Int J Oncol,2005,26(6): 1681-1689.
[51]Paige AJ, Taylor KJ, StewartA, et al. A 700 kb physicalmap of a region of 16q23. 2 homozygously deleted in multip le cancersand spanning the common fragile site FRA16D[J]. Cancer Res,2000,60 (6):1690-1697.
[52]Nunez MI, Rosen DG, Ludes-Meyers JH, et al. WWOX protein expression varies among ovarian carcinoma histotypes and correlates with less favorable outcome [J]. BMC Cancer,2005,10 (5):837-843.
[53]闫洪超,陆晓媛,韩秋峪,等.WWOX mRNA在卵巢上皮性癌组织中的表达及临床意义[J].徐州医学院学报,2007,27(2)：126-128.
[54]IliopoulosD, Guler G, Han SY, et al. Fragile genes as biomarkers:ep igenetic control ofWWOX and FH IT in lung, breast and bladdercancer[J]. Oncogene,2005, 24(9):1625-1633.
[55]周玉龙,徐永健,张珍祥.抑癌基因WWOX在肺腺癌细胞株A549中表达的研究[J].中国癌症杂志,2005,15(3)：234-237.
[56]YendamuriS, KurokiT, TrapassoF, et al. WW domain containingoxidoreductase gene exp ression is altered in non-small cell lung cancer[J]. Cancer Res,2003,63 (4):878-881.
[57]DonatiV, Fontanini G, Dell'OmodarmeM, et al. WWOX expression in different histological types and subtypes of non-small cell lung cancer[J]. Clin Cancer Res, 2007,13:884-891.
[58]Kuroki T,Trapasso F,Shiraishi T,et al. Genetic alterations of tumor suppressor gene WWOX in esophageal squamous cell carcinoma[J]. Cancer Res,2002,62(8):2258-2260.
[59]Yakicier MC,Legoix P,Vaury C,et al. Identification of homozygousdeletions at chromosome 16q23 in aflatoxin B1 exposed hepatocellular carcinoma[J]. Oncogene,2001,20(37):5232-5238.
[60]Park SW,Ludes-Meyers J,Zimonjic DB,et al. Frequent downregulation and loss of WWOX gene exppression in human hepatocellular carcinoma[J]. Br J Cancer,2004,91(4):753-759.
[61]陈锦萍,王效明.PCR检测原发性肝细胞癌WWOX基因表达及意义[J].临床检验杂志,2007,25(5)：364-366.
[62]Matsuo K,Kuroki T,Kitaoka F,et al. Loss of heterozygosity of chromosome 16q in gallbladder carcinoma [J].J Surg Res,2002,102(2):133-136.
[63]顾军,王梅.抑癌基因WWOX在肝外胆管癌中的表达[J].世界华人消化杂志,2007,15(11)：1302-1305.
[64]Kuroki T,Yendamuri S,Trapasso F,et al. The tumor suppressor gene WWOX at FRA16D is involved in pancreatic carcinogenesis [J]. Clin Cancer Res,2004,10(7):2459-2465.
[65]许红霞,周建农.抑癌基因WWOX和FHIT在结直肠癌中的表达及其临床意义[J].南京医科大学学报,2007,27(8)：812-815.
[66]Ishii H, Vecchione A, Furukawa Y, et al. Exp ression of FRA16D/WWOX and FRA3B/FH IT genes in hematopoieticmalignancies[J]. Mol Cancer Res,2003,1 (13):940-947.
[67]Huebner D, Bednarek A, Cat herine L, et all WWOX, the FRA16D gene behaves as a suppressor of tumor growt h1 Cancer Res,2001,61 (15):8068-80731.
[68]Qin HR,Iliopoulos D1A role for the WWOX gene in prostate cancer.Cancer Res,2006,66 (2):123-127.
[69]Akira W, Yoshitaka H, Hirokazu T, et all An opposing view on WWOX protein function as a tumor suppressorl Cancer Research,2003,63 (15) 8629-8633.